GC
CTKB icon

Globeflex Capital’s Cytek Biosciences CTKB Stock Holding History

Globeflex Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-290,511
Closed -$988K – 422
2025
Q2 		$988K Hold
290,511
– – 0.08% 185
2025
Q1 		$1.16M Buy
290,511
+206,077
+244% +$1.07M 0.11% 158
2024
Q4 		$548K Buy
+84,434
New +$503K 0.05% 259

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Globeflex Capital's CTKB Position: Q3 2025 in Review

Globeflex Capital sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 290,511 shares — an estimated $988K sold.

Globeflex Capital first reported a position in CTKB in Q4 2024 and held it in 3 quarters. The position peaked at $1.16M in Q1 2025. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • Globeflex Capital reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • Globeflex Capital sold 290,511 Cytek Biosciences shares in Q3 2025, an estimated $988K.
  • Globeflex Capital first reported a position in Cytek Biosciences in Q4 2024 and held it in 3 quarters.
  • Globeflex Capital's Cytek Biosciences position peaked at $1.16M in Q1 2025.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Globeflex Capital's 13F filing for Q3 2025, filed 12 Nov 2025.